Sign in
Taking people in United KingdomNo phase

Studying immune system signals and response to antipsychotic treatment in psychosis

Compares immune markers in adults with psychosis starting antipsychotics against healthy controls.

Key facts

Who runs it
King's College London
Where
London, United KingdomSee the site
Trial code
Registry title
Immune Mechanisms of Antipsychotic Treatment Response
Status
Recruiting
People taking part
500 people, planned
Started
6 Aug 2025
Expected to end
Jul 2031
Type of study
Observational, 2 groups
Record updated
25 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with psychosis symptoms who are about to start or change to a new regular antipsychotic medicine. It also takes control participants without psychosis or autoimmune disease.

Age
18-65 years
Sex
All sexes can join.
Disease stage
People with current psychosis symptoms that need care from secondary care mental health services, likely linked to a disorder coded ICD F20-F39 in the treating team's opinion. Controls must have no history of psychosis symptoms.
Earlier treatment
People with psychosis must be due to start or change to a new regular antipsychotic medicine. This includes a first treatment, a switch, or restarting one stopped for at least two weeks.

Main reasons for not taking part

  • Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance
  • Taking, or having taken in the last four weeks, medicine that grossly affects immune cells (for example corticosteroids, methotrexate, rituximab)
  • Inability to have blood tests
  • Controls: an active autoimmune disorder
  • Optional lumbar puncture: spinal deformity or surgery, blood thinners within 14 days, clotting disorder, or raised pressure in the head

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Participants with psychosis symptoms:
  • Age 18-65
  • Currently experiencing psychosis symptoms warranting treatment by secondary care mental health services, as confirmed by a psychiatrist involved in their treatment
  • Psychosis symptoms likely to be attributable to a disorder represented by ICD codes F20-F39, in the opinion of the treating clinical team
  • Due to start or change to a new regular antipsychotic medication. (Participants who are initiating antipsychotic treatment for the first time, transitioning to a different antipsychotic medication, or resuming a formerly prescribed antipsychotic medication that was discontinued for a minimum of two weeks may be recruited.); Control Participants
  • Age 18-65
  • No active autoimmune disorder
  • No history of psychosis symptoms

Who cannot take part

  • Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies)
  • Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies)
  • Significant lower spinal deformity (such as spina bifida), injury (such as stenosis) or previous lower spinal surgery
  • Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure
  • Known or suspected clotting disorder
  • Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution
  • History of chronic or recurrent headaches, in the opinion of the investigator
  • Clinically significant abnormality in full blood count
  • Participants with psychosis symptoms:
  • Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance
  • Inability to have blood tests; Control participants:
  • Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance
  • Inability to have blood tests; Optional lumbar puncture only:
  • Known or suspected raised intracranial pressure, assessed by study clinician

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United Kingdom

  • South London and Maudsley NHS Foundation TrustLondon, United KingdomContact: Thomas Pollak, PhDTaking people

About the trial

What the trial wants to find out

The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis symptoms who are about to start or change to a new regular antipsychotic treatment as well as a control group for comparison.

Read full original descriptionShow less

Participants will be assessed at two main timepoints, at visit 1 (Week 0) and at visit 2 (4 +/-2 weeks). For participants with psychosis symptoms visit 1 will take place at the start or change of antipsychotic medication. The studies goal is to identify biomarkers that can aid in diagnosis, prognosis, treatment selection, and tracking treatment response.

The investigators aim to recruit participants from the following groups:

1. Individuals with psychosis symptoms presenting to acute or outpatient services who are due to be started on or change to a new regular antipsychotic medication. 2. Age- and sex-matched control participants without neuropsychiatric disease.

Findings could potentially impact the treatment of psychotic illnesses by offering mechanistic insights into targeted immune-based interventions for these disorders through high-resolution immunophenotyping techniques alongside targeted immunological assays. Ultimately, the research aims to contribute valuable resources for future studies exploring the connection between immune processes and neuropsychiatric conditions.

The 2 groups in the trial

  • Participants with psychosis symptoms
  • Control Participants

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Immune Mechanisms of Antipsychotic Treatment Response
Plain-language title
Studying immune system signals and response to antipsychotic treatment in psychosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06687694, who can take part
Record updated
25 March 2026